Radiation Oncology Committee Meeting Agenda
Chair: Jeff Bogart
Vice-Chair Joseph Salama

PRIORITY DISCUSSION:

1. PHASE II PROPOSAL : SBRT + AVELUMAB (ERNANI)
2. PHASE III TRIAL OF PCI FOR SMALL CELL LUNG CANCER (BROWN)
3. PHASE III TRIAL OF IMMUNOTHERAPY FOR LIMITED SMALL CELL LUNG CANCER (LU 005)
4. BLADER CANCER PHASE II STUDY OF DOSE-DENSE GEMCITABINE PLUS CISPLATIN (DDGC) IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WITH BLADDER PRESERVATION FOR THOSE PATIENTS WHOSE TUMORS HARBOR DELETERIOUS DNA DAMAGE RESPONSE (DDR) GENE ALTERATIONS (A031701) (KWOK)
5. PROSTATE CANCER UPDATE (CHEN)
6. OPPORTUNITIES FOR SECONDARY AT QARC/IROC

ACTIVE STUDIES

Lung Cancer

- AFT-16: Induction PDL-1 inhibition Stage III NSCLC 
  Urbanic
- AFT-07 Veliparib + ChemoRT Stage III NSCLC 
  Salama
- C 30610: Limited Stage Small Cell Intergroup Trial –
  Bogart
- NRG CC003: PCI with or without Hippocampal Avoidance for SCLC 
  Grecola

Breast Cancer

- Alliance A221505 Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction 
  Poppe
- A011202 A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy
NRG Oligometastatic Trials

**CNS**

- **CE.7**  SRS vs WBRT for Multiple Brain Metastases
- **A221208**  Randomized phase II study: Corticosteroids + bevacizumab vs. corticosteroids + placebo (BeSt) for radionecrosis after radiosurgery for brain metastases
- **N0577**  Phase III intergroup study of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy with adjuvant PCV chemotherapy in patients with 1p/19q co-deleted anaplastic glioma or low grade glioma (CODEL)
- **A071102**  A phase II/III randomized trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promoter hypermethylation

**GI Cancer**

- **A021501**, “Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated RT for Borderline Resectable Adenocarcinoma of the Head of the Pancreas”
- **N 1048**: A phase II/III trial of neoadjuvant FOLFOX, with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision (PROSPECT)

**Other**

- **A091605**  Stereotactic body radiotherapy and pembrolizumab in advanced merkel cell carcinoma
- **A061402**  Adjuvant therapy after Radiation for Solitary plasmacytoma

**IROC Update**